JAK2 V617F: How One Mutation Became a Major Criterion for Polycythemia Vera

A routine blood panel comes back with a hemoglobin and hematocrit that are simply too high, and your first job is to sort a benign explanation from a marrow that has taken on a life of its own. This is where JAK2 testing has changed the workflow. A single acquired mutation, JAK2 V617F, is found in more than 95 percent of polycythemia vera cases and is uncommon in people without a myeloproliferative neoplasm, so the World Health Organization ranks it as a major diagnostic criterion. A positive result points hard toward a primary marrow disorder. A negative result, though, does not close the file, because a smaller group carries a mutation elsewhere in the JAK2 gene and a rare few carry neither.

Key points#

• JAK2 V617F is an acquired (not inherited) mutation present in the large majority of polycythemia vera cases.
• Its rarity in the general population is what makes a positive test so informative.
• The 2022 WHO criteria name both JAK2 V617F and JAK2 exon 12 mutations as satisfying the molecular major criterion.
• A negative V617F result in a convincing case should trigger reflex exon 12 testing, not a stop.
• When the red cell mass is genuinely high but molecular testing is negative, the bone marrow biopsy carries the reasoning.

The problem the test is trying to solve#

A high red cell count has two broad explanations. In the secondary form, the marrow is responding correctly to a real signal: chronic low oxygen, sleep-disordered breathing, high altitude, heavy smoking, or a source of extra erythropoietin somewhere in the body. In polycythemia vera, the marrow is not responding to anything. It is making red cells on its own schedule, a clonal process driven by one abnormal stem cell and its descendants outgrowing normal marrow.

Telling these apart used to lean heavily on indirect measures and marrow appearance. The value of a molecular marker is that it speaks to the mechanism directly. If the growth signal inside the cell is stuck in the on position, that is a property of the disease itself, not of the patient's oxygen level or smoking habit.

What JAK2 V617F changes inside the cell#

JAK2 is a signaling enzyme tethered just inside blood-forming cells. Its normal job is to relay messages from surface receptors, including the erythropoietin receptor that governs red cell production, and then to fall silent until the next message arrives. Think of it as a switch that should flip on only when a hormone knocks at the door.

The V617F mutation swaps one amino acid (valine for phenylalanine at position 617) in the regulatory region that holds that switch off. The altered enzyme no longer waits for the knock. It signals continuously, so the marrow behaves as though it is being told to produce red cells around the clock even when erythropoietin is low. That specific combination, a high red cell mass sitting alongside a suppressed erythropoietin level, is the biological fingerprint of polycythemia vera. Because the change is acquired in blood cells rather than passed down through families, it also marks the process as clonal, which is exactly the feature the diagnostic criteria are written to catch.

Why it earned major-criterion status#

A diagnostic marker is only as good as two numbers pulling against each other: how often it shows up in the people who truly have the disease, and how seldom it shows up in the people who do not. Both belong in your head. JAK2 V617F does well on both counts. It is present in the large majority of confirmed cases and it is scarce in the general population without a myeloproliferative neoplasm.

The 2022 WHO classification lists three major criteria for polycythemia vera: an elevated hemoglobin, hematocrit, or red cell mass; a bone marrow biopsy showing overgrowth of all three cell lines; and the presence of a JAK2 V617F or JAK2 exon 12 mutation. A low serum erythropoietin serves as the minor criterion. A diagnosis generally requires all three major criteria, or the first two together with the minor one. Ranking the mutation among the majors reflects a practical judgment: in a patient with a genuinely high red cell mass, a positive JAK2 result argues strongly for a primary marrow disorder over any secondary cause.

That shift has a real-world downside as well. A 2014 analysis in Annals of Hematology, reviewing how the JAK2 V617F assay was used within a diagnostic pathway, found that a sizable share of mutation-positive patients were labeled with polycythemia vera on molecular grounds alone, without a supporting erythropoietin level or marrow study. The convenience of a single test can tempt you into skipping the findings that would otherwise confirm the picture. A strong marker is an anchor, not a substitute for the rest of the evaluation.

The exon 12 group, and why the criterion names it#

Not every positive JAK2 test is the V617F variant. In 2007, a New England Journal of Medicine report described a separate cluster of gain-of-function mutations in JAK2 exon 12, found in patients who tested negative for V617F. These patients often presented with isolated erythrocytosis, a somewhat different marrow appearance, and a low erythropoietin. Exon 12 mutations are uncommon in absolute terms, making up a low single-digit percentage of all polycythemia vera, but within the V617F-negative subgroup they account for a large share of the remaining cases.

This is why the WHO criterion reads V617F or exon 12. Naming both closes a gap that a V617F-only test would leave wide open, and it carries a concrete ordering rule: when a first-line V617F assay comes back negative in someone with a convincing high red cell mass and a low erythropoietin, the sensible next move is reflex testing for exon 12 rather than abandoning the marrow as the culprit.

When the test comes back negative#

A negative result is where your reasoning has to slow down, because the meaning of any test depends on how likely the disease was before you ran it. In a person whose high hematocrit is well explained by dehydration, smoking, or altitude, a negative JAK2 result mostly reaffirms a low starting suspicion. In a person with a truly elevated red cell mass and a suppressed erythropoietin, the same negative result carries different weight, since a small number of real cases fall outside both known JAK2 hotspots.

A 2008 study in the American Journal of the Medical Sciences, looking at how V617F testing was used and how often it altered a diagnosis in an academic practice, illustrates the point: the test is most useful for clarifying uncertain cases, not for replacing the workup. A negative test does not on its own exclude polycythemia vera when the clinical and laboratory picture still points that way. That is precisely the situation in which the other major criteria, the bone marrow biopsy above all, do the work a molecular test could not.